NotesFAQContact Us
Collection
Advanced
Search Tips
Showing all 2 results Save | Export
Brief Report: Social Disability in Autism Spectrum Disorder--Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto – Journal of Autism and Developmental Disorders, 2013
There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to…
Descriptors: Autism, Pharmacology, Effect Size, Pervasive Developmental Disorders
A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation
Peer reviewed Peer reviewed
Direct linkDirect link
Hellings, Jessica A.; Zarcone, Jennifer R.; Reese, R. Matthew; Valdovinos, Maria G.; Marquis, Janet G.; Fleming, Kandace K.; Schroeder, Stephen R. – Journal of Autism and Developmental Disorders, 2006
Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8-56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance…
Descriptors: Drug Therapy, Mental Retardation, Pervasive Developmental Disorders, Children